CliffBio
small molecule

SINCALIDE

SINCALIDE

Loss of exclusivityApril 2038latest FDA-listed patent expiry
CompanyMaia →View the full company profile on CliffBio

Drug detail

Brand nameSINCALIDE
Active ingredientSINCALIDE
Strength0.005MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2022
Marketing statusRX

Listed patents

PatentExpiresType
11737983April 2038product
11318100April 2038product
11110063April 2038product

More from Maia

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SINCALIDE patent cliff — loss of exclusivity April 2038 | CliffBio